Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients

被引:78
|
作者
Sun, Xinchen [2 ]
Li, Fan [2 ]
Sun, Ning [2 ]
Qin Shukui [1 ]
Chen Baoan [2 ]
Feng Jifeng
Lu, Cheng [3 ]
Lu Zuhong [3 ]
Cheng Hongyan [2 ]
Cao YuanDong [2 ]
Ji Jiazhong [4 ]
Zhou Yingfeng [4 ]
机构
[1] 81st Hosp PLA, Dept Oncol, Nanjing 210034, Jiangsu, Peoples R China
[2] Southeast Univ, Zhongda Hosp, Nanjing 210009, Jiangsu, Peoples R China
[3] Southeast Univ, Lab Mol & Biomol Elect, Nanjing 210096, Jiangsu, Peoples R China
[4] Jiangbei People Hosp, Dept Oncol, Nanjing 210048, Jiangsu, Peoples R China
关键词
Single nucleotide polymorphism; Gene-chip/microarrays; XRCC1; XPG; Non-small cell lung cancer (NSCLC); Chemotherapy; NUCLEOTIDE EXCISION-REPAIR; PLUS CARBOPLATIN; DNA-ADDUCT; CISPLATIN; GENES; METHYLATION; BIOMARKERS; SURVIVAL; TRIAL; ERCC2;
D O I
10.1016/j.lungcan.2008.11.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Platinum-based chemotherapeutics is the most common regimens for advanced NSCLC patients. However, it is difficult to identify platinum resistance in clinical treatment. Genetic factors are thought to represent important determinants of drug efficacy. In this study, we investigated whether single nucleotide polymorphisms (SNPs)in Xeroderma pigmentosum group G (XPG) and X-ray repair cross complementing group 1 (XRCC1) were associated with the tumor response in non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy in Chinese population. Totally 82 patients with advanced NSCLC were routinely treated with cisplatin or carboplatin-based chemotherapy, and clinical response was evaluated after 2-3 cycles. And 3D (three dimensions) polyacrylamide gel-based DNA microarray method was used to evaluate the genotypes of XRCC1 194 Arg/Trp, XRCC1 399Arg/Gln, XPG 46His/His and XPG 1104His/Asp in DNA from peripheral lymphocytes. We found that there was a significantly increased chance of treatment response to platinum-based chemotherapy with the XRCC1 194Arg/Trp genotype (odds ratio 0.429; 95% CI 0.137-1.671; P = 0.035). The polymorphism of XPG 46His/His was found to be associated with clinical response in NSCLC patients P = 0.047, not detected between chemotherapy response and SNPs of XRCC1 399Arg/Gln or XPG 1104His/Asp (P = 0.997 0.561, respectively). Our study showed that the polymorphic status of XRCC1 194Arg/Trp might be a predictive marker of treatment response for advanced NSCLC patients and those of XPG His46His was associated with susceptibility of chemotherapy. The 3D polyacrylamide gel-based DNA microarray method was accurate, high-throughput and inexpensive, especially suitable for a large scale of SNP genotyping in population. Crown Copyright (C) 2008 Published by Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:230 / 236
页数:7
相关论文
共 50 条
  • [1] Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer
    Jin, Z. Y.
    Zhao, X. T.
    Zhang, L. N.
    Wang, Y.
    Yue, W. T.
    Xu, S. F.
    [J]. GENETICS AND MOLECULAR RESEARCH, 2014, 13 (03): : 7617 - 7625
  • [2] Relationship of XRCC1 and XPD genetic polymorphisms and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer
    Huang, Xin-En
    Tang, J.
    Feng, J.
    Jiang, W.
    Pan, L.
    Chen, J.
    Sun, W.
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2009, 63 (05) : 323 - 323
  • [3] XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy
    Zou, H. Z.
    Zhao, Y. Q.
    [J]. GENETICS AND MOLECULAR RESEARCH, 2015, 14 (01) : 500 - 506
  • [4] Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients
    Zhou, Fei
    Yu, Zhuang
    Jiang, Tao
    Lv, Hongying
    Yao, Ruyong
    Liang, Jun
    [J]. SWISS MEDICAL WEEKLY, 2011, 141
  • [5] Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis
    Li, L.
    Wan, C.
    Wen, F. Q.
    [J]. GENETICS AND MOLECULAR RESEARCH, 2014, 13 (02): : 3772 - 3786
  • [6] Predictive Value of XRCC1 Gene Polymorphisms on Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-analysis
    Wu, Junjie
    Liu, Jie
    Zhou, Yuhao
    Ying, Jun
    Zou, Houdong
    Guo, Shicheng
    Wang, Lei
    Zhao, Naiqing
    Hu, Jianjun
    Lu, Daru
    Jin, Li
    Li, Qiang
    Wang, Jiu-Cun
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (14) : 3972 - 3981
  • [7] No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy
    Yuan, Peng
    Liu, Li
    Wu, Chen
    Zhong, Rong
    Yu, Dianke
    Wu, Jing
    Xu, Yihua
    Nie, Shaofa
    Miao, Xiaoping
    Sun, Yan
    Xu, Binghe
    Lin, Dongxin
    [J]. CANCER BIOLOGY & THERAPY, 2010, 10 (09) : 858 - 863
  • [8] Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer
    Hu, Weicai
    Pan, Jinbing
    Zhao, Pu
    Yang, Guangyu
    Yang, Shujuan
    [J]. TUMOR BIOLOGY, 2014, 35 (06) : 5561 - 5567
  • [9] Lack of Influence of XRCC1 and XPD Gene Polymorphisms on Outcome of Platinum-based Chemotherapy for Advanced Non Small Cell Lung Cancers
    Yao, Cheng-Yun
    Huang, Xin-En
    Li, Chao
    Shen, Hong-Bing
    Shi, Mei-Qi
    Feng, Ji-Feng
    Pan, Liang-Xi
    Tang, Jin-Hai
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2009, 10 (05) : 859 - 864
  • [10] Polymorphisms and haplotypes in XRCC1 and risk of advanced non-small cell lung cancer
    Kim, In-Suk
    Lee, Gyeong-Won
    [J]. CANCER RESEARCH, 2010, 70